875 related articles for article (PubMed ID: 16533938)
1. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
[TBL] [Abstract][Full Text] [Related]
2. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
4. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel.
Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A
Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230
[TBL] [Abstract][Full Text] [Related]
5. Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
Iijima R; Ndrepepa G; Mehilli J; Neumann FJ; Schulz S; ten Berg J; Bruskina O; Dotzer F; Dirschinger J; Berger PB; Schömig A; Kastrati A
Clin Res Cardiol; 2008 Mar; 97(3):160-8. PubMed ID: 18046527
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
7. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
[TBL] [Abstract][Full Text] [Related]
8. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.
Schulz S; Mehilli J; Ndrepepa G; Dotzer F; Dommasch M; Kufner S; Birkmeier KA; Tiroch K; Byrne RA; Schömig A; Kastrati A
Clin Res Cardiol; 2011 Aug; 100(8):691-9. PubMed ID: 21384174
[TBL] [Abstract][Full Text] [Related]
9. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
[TBL] [Abstract][Full Text] [Related]
10. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schömig A
Eur Heart J; 2008 Feb; 29(4):455-61. PubMed ID: 18158289
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
13. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
15. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Ibbotson T; McGavin JK; Goa KL
Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
18. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
20. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Moliterno DJ;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]